KSI-101 is poised to fulfill the core unmet need in MESI based on its potential to be a disease modifying, high-strength, locally administered and safe biologic Safety Efficacy Illustrative IVT anti-VEGF monotherapy Systemic immuno- suppressants High Less complications • Dual anti-IL-6 and anti-VEGF inhibition • Potential for disease modifying effect based on its synergistic inhibition of IL-6 and VEGF, as demonstrated in preclinical models and clinical cases • High strength formulation (100 mg/mL) and high potency provide the fire-power needed to treat “angry” inflammation and macular edema • Local (intravitreal) administration • Safety profile in line with intravitreally administered biologics (i.e., Eylea, Lucentis) Unified treatment irrespective of presumed etiology KSI-101 is designed to address the core unmet need Core unmet need open Steroids 61 • Targets both IL-6 and VEGF disease drivers • Potentially disease modifying • High strength • Potent • Minimally invasive • Better safety